Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Diego R. Pereira"'
Autor:
Pamella G. Gutierres, Diego R. Pereira, Nataly L. Vieira, Lilian F. Arantes, Nelson J. Silva, Kristian A. Torres-Bonilla, Stephen Hyslop, Karen Morais-Zani, Rosa M. B. Nogueira, Edward G. Rowan, Rafael S. Floriano
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2022)
Varespladib (VPL) was primarily developed to treat inflammatory disturbances associated with high levels of serum phospholipase A2 (PLA2). VPL has also demonstrated to be a potential antivenom support agent to prevent PLA2-dependent effects produced
Externí odkaz:
https://doaj.org/article/34f61b212fb147f69bb0d5fa3473d38b
Autor:
Pamella G. Gutierres, Diego R. Pereira, Nataly L. Vieira, Lilian F. Arantes, Nelson J. Silva, Kristian A. Torres-Bonilla, Stephen Hyslop, Karen Morais-Zani, Rosa M. B. Nogueira, Edward G. Rowan, Rafael S. Floriano
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2022)
Frontiers in Pharmacology, Vol 12 (2022)
Varespladib (VPL) was primarily developed to treat inflammatory disturbances associated with high levels of serum phospholipase A2 (PLA2). VPL has also demonstrated to be a potential antivenom support agent to prevent PLA2-dependent effects produced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2c7e357e7d9f10a7b59d78f69a916b6
https://strathprints.strath.ac.uk/79312/1/Gutierres_etal_FP_2021_Action_of_Varespladib_LY_315920_a_phospholipase_A2_inhibitor_on_the_enzymatic_coagulant_and_haemorrhagic_activities.pdf
https://strathprints.strath.ac.uk/79312/1/Gutierres_etal_FP_2021_Action_of_Varespladib_LY_315920_a_phospholipase_A2_inhibitor_on_the_enzymatic_coagulant_and_haemorrhagic_activities.pdf
